<DOC>
	<DOCNO>NCT01526785</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety treatment 4000 litre ( L ) alglucosidase alfa ( LumizymeÂ® ) Pompe participant .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Alglucosidase Alfa Produced 4000 L Scale Pompe Disease</brief_title>
	<detailed_description />
	<mesh_term>Glycogen Storage Disease Type II</mesh_term>
	<criteria>A participant might meet follow criterion eligible study . 1 . The participant and/or parent/legal guardian willing able provide sign informed consent . 2 . The participant might least 1 year age time informed consent . 3 . The participant diagnosis Pompe disease might receive treatment 160 L alglucosidase alfa prior screen . 4 . The participant , female childbearing potential , might negative pregnancy test ( urine betahuman chorionic gonadotropin ) baseline . Note : female participant childbearing potential sexually mature male might agree use medically accept method contraception throughout study . A participant met follow criterion exclude study . 1 . The participant within past 3 month receive currently receive investigational product 160 L alglucosidase alfa currently participate another clinical treatment study . 2 . The participant , opinion Investigator , clinically unstable would expect survive completion 52week treatment period . 3 . The participant and/or parent/legal guardian , opinion Investigator , unable adhere requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>